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SHORT COMMUNICATION
The modifying effect of beta-carotene on radiation and chemotherapy
induced oral mucositis
E.E.D. Mills
National Accelerator Centre and Department ofRadiotherapy Tygerberg Hospital and University ofStellenbosch, Tygerberg,
Republic ofSouth Africa.
The purpose of this study was to monitor the dose
modifying effect of supplemental dietry beta-carotene on the
progression of the oral mucosal reaction and treatment
outcome during an intensive course of synchronous radiation
and chemotherapy. Tumour response and long term normal
tissue changes have been carefully recorded.
Twenty patients with advanced squamous carcinoma of
the mouth, who received 60 Gy telecobalt therapy given in 30
daily fractions with synchronous chemotherapy comprising
vincristine, methotrexate and bleomycin, were randomised to
receive standard diet with supplemental beta carotene (study
patients) or standard diet only with no placebo (control
patients). Patients were matched for performance status
(>H2 (AJC)) and age (av. 57 years). All patients gave
informed consent, were hospitalised, on routine mouth care
and restrained from smoking during treatment. There were
no non-smokers. The chemotherapy schedule as described by
O'Connor et al. (1977) comprised:
At 00h vincristine (V) 2mg i.v. stat
06h bleomycin (B) 30 mg i.m. stat
24h methotrexate (M) 200mg in saline 24h infusion
followed by leucovorin 6 mg i.m. 6 hourly x 4.
Chemotherapy was synchronised for administration the
weekend prior to the start and following the completion of
radiotherapy and after 20Gy and 40Gy during the third and
sixth week respectively for 7 days. Telecobalt 60Gy in 30
fractions over 8 weeks was given with Ellis-type
compensation for tissue obliquity and full skin sparing
characteristics. Beta-carotene dosage commenced at 250 mg
daily up to day 21 and thereafter 75 mg daily for the
duration of the treatment. Testing beta-carotene has the
advantage of avoiding hypervitaminosis A. Hypercarotenosis
as far as is known in all its forms is entirely harmless and
the joint FAO/WHO Expert Committee on Food Additives
estimated the acceptable daily intake of beta-carotene for a
70kg adult to be 350mg per day (WHO), 1974. The oral
mucosal reaction was scored weekly by consensus amongst 3
observers in accordance with the grading system used by the
Tygerberg Hospital Head and Neck Oncology Clinic (Table
I).
The difference in the range of acute mucosal reactions
recorded in the two groups of patients is shown in Table II.
When analysed in terms of patient weeks a significantly
(P<0.025) less severe reaction was measurable in the
patients receiving supplemental beta-carotene. The time
sequence over which the severe reactions developed is
depicted in Figure 1.
Remission rate was not significantly different in the two
groups of patients. At the completion of treatment 8/20
(40%) patients had complete remission and 3/20 patients had
partial remission (>50% reduction of the greatest diameter).
Long term follow up at 29 to 45 months (mean 36) showed
local tumour control was sustained in 5 patients of whom
Table I The intensity of the acute mucosal reaction as
graded from 0-IV
Mucosal reaction
Grade 0 No reaction
Grade I Erythema
Grade II Patchy membranous mucositis
Grade III Superficial confluent membranous mucositis
Grade IV Deep confluent membranous mucositis
Table II The difference in the range of acute mucosal reactions
scored by week of treatment in the two groups ofpatients
Week of treatment
2 3 4 5 6 7 Total
Grade No. patients patient-weeks
0 8 4 0 0 0 0 12
I 2 5 0 0 0 1 81 Mild
Study II 0 1 7 8 1 2 191 reaction
Patients III 0 0 2 0 3 2 71 aSevere
(n= 10) IV 0 0 1 2 6 5 141 reaction
O 9 1 0 0 0 0 10
I 0 3 0 0 0 0 3- Mild
Control II 1 4 2 2 1 1 11 reaction
Patients III 0 2 5 2 3 2 141 aSevere
(n= 10) IV 0 0 3 6 6 7 221 reaction
aDifference in severe (Grade III and IV) reactions in patient-
weeks is significant (P<0.025 using Chi-squared test with 2
degrees of freedom).
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Figure 1 Numbers of patients showing severe (Grade III/IV)
acute mucosal reaction. Patients receiving supplemental beta
carotene (- ) developed severe reactions later and these tended
to be less intense than control patients ( ) in the fourth and
fifth weeks of treatment.
two from the control group had lymph node involvement.
One study patient died at 16 months of unrelated cause
while two others (one from each group) were lost to follow-
up at 5 and 8 months respectively.
Received 30 September 1987; and in revised form, 29 December
1987.
Br. J. Cancer (1988), 57, 416-417 0'. The Macmillan Press Ltd., 1988 A
5BETA-CAROTENE: DOSE MODIFYING EFFECT 417
Of those patients who failed treatment all died with
locoregional disease. They comprised 6 patients from each of
the study and control arms. The mean tumour-free period
was 5 and 4 months and the survival period 11 and 12
months respectively.
Late responding tissue changes were limited to mild
oedema and induration of the soft tissues of the neck in all 5
surviving patients. Two patients with mandibular infiltration
had non-healing and progressive disease.
Recent years have seen a considerable interest in the role
of vitamin A in the induction and treatment of cancer.
Numerous synthetic derivatives varying in mode of action,
efficacy and toxicity, have shown significant therapeutic
benefits when used as an adjuvant to radiotherapy and
chemotherapy in animal tumour systems (Seifter et al.,
1983). These compounds have however been little used in
clinical oncology. This is probably related to the severe
toxicity experienced at effective dose levels and because of
sporadic laboratory reports of tumour growth enhancement
by vitamin A administration (Levij & Polliack, 1969).
The pro-vitamin A (beta-carotene) when used as an
adjunct to radiotherapy in the treatment of transplantable
adenocarcinoma in mice (Seifter et al., 1983) significantly
improved tumour reduction, survival and wound healing.
This anti-tumour effect was more pronounced with beta-
carotene supplementation than with vitamin A. In addition
those animals receiving such compound showed diminished
local and whole body radiation toxic effects. Beta carotene is
said to be the most efficient quencher of singlet oxygen thus
far known to man and is naturally protective against the
damaging effects of ultra violet irradiation in plants under-
going photosynthesis (Foote, 1976). This and the fact that its
use in man is reportedly safe (WHO, 1974) prompted the
author to utilise large doses of supplemental beta-carotene
during a course of intensive combination chemotherapy and
radiotherapy for advanced head and neck epidermoid
tumours.
Although the small number of patients studied militates
against the statistical validity of the results reported, it does
suggest that a protective action of beta-carotene is exerted
on the mucosal membrane within the radiation fields used.
This trend is not reflected in the observations made on
late responding tissue changes. There is likewise no
difference in tumour control rates or survival amongst the
patients studied. This is notwithstanding the reported
inhibitory effect of both vitamin A and beta-carotene on
tumour growth in experimental systems which has been well
documented and reviewed (Lotan, 1980; Mills, 1983).
The above results and freedom from toxic side effects
suggest that beta-carotene should be further studied as an
adjunct to radiation therapy of tumours.
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